Related Experiment Videos
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013
S A Scott1, K Sangkuhl, C M Stein
1Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Clinical Pharmacology and Therapeutics
|May 24, 2013
Summary
Genetic variations in CYP2C19 affect clopidogrel activation, increasing cardiovascular risks in acute coronary syndrome patients. Guidelines now emphasize genotype-directed antiplatelet therapy for better outcomes.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Drug Metabolism
Background:
- Cytochrome P450 (CYP)2C19 is crucial for activating the antiplatelet drug clopidogrel.
- Loss-of-function CYP2C19 alleles reduce active metabolite formation, leading to diminished platelet inhibition.
Purpose of the Study:
- To update clinical guidelines regarding CYP2C19 genotype-directed antiplatelet therapy.
- To emphasize appropriate indications and refined recommendations for specific CYP2C19 alleles.
Main Methods:
- Literature review on CYP2C19 function and clopidogrel therapy.
- Analysis of clinical outcomes in patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI).
Main Results:
- CYP2C19 loss-of-function alleles are associated with increased risk of adverse cardiovascular events in clopidogrel-treated ACS patients.
- Reduced platelet inhibition is observed in patients with these genetic variations.
Conclusions:
- Clinical practice guidelines have been updated to incorporate CYP2C19 genotype information.
- Genotype-directed antiplatelet therapy is recommended for optimizing treatment and reducing cardiovascular event risk in specific patient populations.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...